Views & Analysis Deep Dive: Oncology magazine launched today Are cancer screening and diagnosis swift enough, and how effective are the latest tailored drugs?
News With all eyes on IO, Tagrisso could be AZ's ace card AstraZeneca saw revenues decline by 3% and earnings per share fall 5% in 2016 as the expiry of blockbuster Crestor took its toll.
Partner Content Partner Content Immuno-Oncology: A 360° View in NYC this February The Conference Forum has announced that the 3rd annual
Views & Analysis ESMO review: advances in immunotherapy, EMA dialogue and pa... QuintilesIMS’s Cristina Oliva talks to pharmaphorum about her personal highlights from this year’s congress.
News Three's a crowd as Tecentriq approved in lung cancer Cancer immunotherapy approved in second line.
News Adaptimmune revives ovarian cancer trial T-cell trial will include controversial chemo agent fludarabine.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
